Telmisartan use in rats with preexisting osteoporotics bone disorders increases bone microarchitecture alterations via PPARγ

Publication date: Available online 10 October 2019Source: Life SciencesAuthor(s): Antonio Marcos Birocale, Antonio Ferreira de Melo, Pollyana Peixoto, Phablo Wendell Costalonga Oliveira, Leandro Dias Gonçalves Ruffoni, Liliam Masako Takayama, Breno Valentim Nogueira, Keico Okino Nonaka, Rosa Maria Rodrigues Pereira, José Martins de Oliveira, Nazaré Souza BissoliAbstractAimsTelmisartan (TEL), an angiotensin II type I receptor blocker and PPARγ partial agonist, has been used for to treat hypertension. It is known that PPARγ activation induces bone loss. Therefore, we evaluate the effects of telmisartan on PPARγ protein expression, biomechanics, density and bone microarchitecture of femurs and lumbar vertebrae in SHR ovariectomized animals, a model of hypertension in which preexisting bone impairment has been demonstrated.Main methodsSHR females (3 months old) were distributed into four groups: sham (S), sham + TEL (ST), OVX (C) and OVX + TEL (CT). TEL (5 mg/kg/day) or vehicle were administered according to the groups. After the protocol, blood pressure was measured and density, microarchitecture and biomechanics of bone were analyzed. Western blotting analysis was performed to evaluate PPARγ protein expression in the bones.Key findingsCastration induced a deleterious effect on mineral density and trabecular parameters, with telmisartan enhancing such effects. Telmisartan increased PPARγ levels, which were at their highest when the treatment was combined with castra...

Source: Life Sciences - October 11, 2019 Category: Biology Source Type: research